Placebo Responses and Their Clinical Implications in Fibromyalgia: A Meta-Analysis Using SSRI and SNRI Trials
Background: Fibromyalgia (FM) is a chronic primary pain condition, associated with widespread musculoskeletal pain, disturbed sleep, fatigue, cognitive dysfunction, and a range of comorbid conditions such as irritable bowel syndrome, and depression. Despite its high prevalence of 2% in the general p...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-12-01
|
| Series: | Frontiers in Pain Research |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fpain.2021.750523/full |
| _version_ | 1818422838817718272 |
|---|---|
| author | Helen Koechlin Helen Koechlin Anna Kharko Tamara Probst Julia Pradela Stefan Buechi Cosima Locher Cosima Locher Cosima Locher Cosima Locher |
| author_facet | Helen Koechlin Helen Koechlin Anna Kharko Tamara Probst Julia Pradela Stefan Buechi Cosima Locher Cosima Locher Cosima Locher Cosima Locher |
| author_sort | Helen Koechlin |
| collection | DOAJ |
| description | Background: Fibromyalgia (FM) is a chronic primary pain condition, associated with widespread musculoskeletal pain, disturbed sleep, fatigue, cognitive dysfunction, and a range of comorbid conditions such as irritable bowel syndrome, and depression. Despite its high prevalence of 2% in the general population, FM continues to pose scientific and clinical challenges in definition, etiology, and day-to-day management. In terms of treatment, FM can be treated with selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs).Objective: Patients with FM and other chronic primary pain syndromes are known to experience substantial and clinically relevant placebo effects. An update of the placebo responses for various outcomes in the FM population and especially a discussion about clinical implications is therefore needed.Methods: We used data from a large data pool that includes randomized controlled trials (RCTs) examining within-placebo mean change scores of baseline vs. follow-up assessments in FM trials of SSRIs and SNRIs. The primary outcomes were pain, functional disability, and depression and using different scales. We assessed heterogeneity of included trials.Results: A total of 29 RCTs with N = 8,453 patients suffering from FM were included in our analysis. Within-placebo mean change scores of baseline vs. follow-up assessments were large for pain (mean change = 2.31, 95% CI: 0.42–4.21, p = 0.017), functional disability (mean change = 3.31, 95% CI: 2.37–4.26, p < 0.000), and depression (mean change = 1.55, 95% CI: 0.92–2.18, p < 0.000). Heterogeneity was found to be large for all outcomes.Impact: Our results provide preliminary evidence that placebo responses, which also consist of non-specific effects, might play a role in the treatment of FM. Furthermore, we highlight limitations of our analyses and make suggestions for future studies. |
| first_indexed | 2024-12-14T13:32:37Z |
| format | Article |
| id | doaj.art-bbc7d083a89a43c39a5fa1aff83a3d43 |
| institution | Directory Open Access Journal |
| issn | 2673-561X |
| language | English |
| last_indexed | 2024-12-14T13:32:37Z |
| publishDate | 2021-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pain Research |
| spelling | doaj.art-bbc7d083a89a43c39a5fa1aff83a3d432022-12-21T22:59:40ZengFrontiers Media S.A.Frontiers in Pain Research2673-561X2021-12-01210.3389/fpain.2021.750523750523Placebo Responses and Their Clinical Implications in Fibromyalgia: A Meta-Analysis Using SSRI and SNRI TrialsHelen Koechlin0Helen Koechlin1Anna Kharko2Tamara Probst3Julia Pradela4Stefan Buechi5Cosima Locher6Cosima Locher7Cosima Locher8Cosima Locher9Division of Clinical Psychology and Psychotherapy, Faculty of Psychology, University of Basel, Basel, SwitzerlandDepartment of Anesthesiology, Critical Care and Pain Medicine, Boston Children's Hospital and Harvard Medical School, Boston, MA, United StatesFaculty of Health, University of Plymouth, Plymouth, United KingdomDivision of Clinical Psychology and Psychotherapy, Faculty of Psychology, University of Basel, Basel, SwitzerlandDivision of Clinical Psychology and Psychotherapy, Faculty of Psychology, University of Basel, Basel, SwitzerlandClinic for Psychotherapy and Psychosomatics “Hohenegg”, Meilen, SwitzerlandDivision of Clinical Psychology and Psychotherapy, Faculty of Psychology, University of Basel, Basel, SwitzerlandFaculty of Health, University of Plymouth, Plymouth, United KingdomClinic for Psychotherapy and Psychosomatics “Hohenegg”, Meilen, SwitzerlandDepartment of Consultation-Liaison Psychiatry and Psychosomatic Medicine, University Hospital Zurich, Zurich, SwitzerlandBackground: Fibromyalgia (FM) is a chronic primary pain condition, associated with widespread musculoskeletal pain, disturbed sleep, fatigue, cognitive dysfunction, and a range of comorbid conditions such as irritable bowel syndrome, and depression. Despite its high prevalence of 2% in the general population, FM continues to pose scientific and clinical challenges in definition, etiology, and day-to-day management. In terms of treatment, FM can be treated with selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs).Objective: Patients with FM and other chronic primary pain syndromes are known to experience substantial and clinically relevant placebo effects. An update of the placebo responses for various outcomes in the FM population and especially a discussion about clinical implications is therefore needed.Methods: We used data from a large data pool that includes randomized controlled trials (RCTs) examining within-placebo mean change scores of baseline vs. follow-up assessments in FM trials of SSRIs and SNRIs. The primary outcomes were pain, functional disability, and depression and using different scales. We assessed heterogeneity of included trials.Results: A total of 29 RCTs with N = 8,453 patients suffering from FM were included in our analysis. Within-placebo mean change scores of baseline vs. follow-up assessments were large for pain (mean change = 2.31, 95% CI: 0.42–4.21, p = 0.017), functional disability (mean change = 3.31, 95% CI: 2.37–4.26, p < 0.000), and depression (mean change = 1.55, 95% CI: 0.92–2.18, p < 0.000). Heterogeneity was found to be large for all outcomes.Impact: Our results provide preliminary evidence that placebo responses, which also consist of non-specific effects, might play a role in the treatment of FM. Furthermore, we highlight limitations of our analyses and make suggestions for future studies.https://www.frontiersin.org/articles/10.3389/fpain.2021.750523/fullplacebofibromyalgiaantidepressantsSSRIsSNRIsmeta-analysis |
| spellingShingle | Helen Koechlin Helen Koechlin Anna Kharko Tamara Probst Julia Pradela Stefan Buechi Cosima Locher Cosima Locher Cosima Locher Cosima Locher Placebo Responses and Their Clinical Implications in Fibromyalgia: A Meta-Analysis Using SSRI and SNRI Trials Frontiers in Pain Research placebo fibromyalgia antidepressants SSRIs SNRIs meta-analysis |
| title | Placebo Responses and Their Clinical Implications in Fibromyalgia: A Meta-Analysis Using SSRI and SNRI Trials |
| title_full | Placebo Responses and Their Clinical Implications in Fibromyalgia: A Meta-Analysis Using SSRI and SNRI Trials |
| title_fullStr | Placebo Responses and Their Clinical Implications in Fibromyalgia: A Meta-Analysis Using SSRI and SNRI Trials |
| title_full_unstemmed | Placebo Responses and Their Clinical Implications in Fibromyalgia: A Meta-Analysis Using SSRI and SNRI Trials |
| title_short | Placebo Responses and Their Clinical Implications in Fibromyalgia: A Meta-Analysis Using SSRI and SNRI Trials |
| title_sort | placebo responses and their clinical implications in fibromyalgia a meta analysis using ssri and snri trials |
| topic | placebo fibromyalgia antidepressants SSRIs SNRIs meta-analysis |
| url | https://www.frontiersin.org/articles/10.3389/fpain.2021.750523/full |
| work_keys_str_mv | AT helenkoechlin placeboresponsesandtheirclinicalimplicationsinfibromyalgiaametaanalysisusingssriandsnritrials AT helenkoechlin placeboresponsesandtheirclinicalimplicationsinfibromyalgiaametaanalysisusingssriandsnritrials AT annakharko placeboresponsesandtheirclinicalimplicationsinfibromyalgiaametaanalysisusingssriandsnritrials AT tamaraprobst placeboresponsesandtheirclinicalimplicationsinfibromyalgiaametaanalysisusingssriandsnritrials AT juliapradela placeboresponsesandtheirclinicalimplicationsinfibromyalgiaametaanalysisusingssriandsnritrials AT stefanbuechi placeboresponsesandtheirclinicalimplicationsinfibromyalgiaametaanalysisusingssriandsnritrials AT cosimalocher placeboresponsesandtheirclinicalimplicationsinfibromyalgiaametaanalysisusingssriandsnritrials AT cosimalocher placeboresponsesandtheirclinicalimplicationsinfibromyalgiaametaanalysisusingssriandsnritrials AT cosimalocher placeboresponsesandtheirclinicalimplicationsinfibromyalgiaametaanalysisusingssriandsnritrials AT cosimalocher placeboresponsesandtheirclinicalimplicationsinfibromyalgiaametaanalysisusingssriandsnritrials |